Trial Profile
Phase 1 Study of Nivolumab in Combination With Tocilizumab for Treatment of Patients With Relapsed Hematological Malignancies Post-allogeneic Transplant
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Tocilizumab (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes
- Focus Adverse reactions
- 19 Jul 2020 Status changed from active, no longer recruiting to discontinued due to COVID19 challenges.
- 11 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.